Aberrant Glycogen Modulates Metabolism in Ewing’s Sarcoma
异常糖原调节尤文氏肉瘤的代谢
基本信息
- 批准号:10303334
- 负责人:
- 金额:$ 3.97万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-01 至 2023-08-31
- 项目状态:已结题
- 来源:
- 关键词:5&apos-AMP-activated protein kinaseAdolescentAdolescent and Young AdultAffectAgeAggressive behaviorArchitectureBiochemicalBiologicalBiologyBone TissueCRISPR/Cas technologyCell physiologyCellular Metabolic ProcessChildChildhoodClinicalComprehensionCoupledCyclic AMP-Dependent Protein KinasesCytoplasmic GranulesDataDepositionDiagnosisDiseaseEWS-FLI1 fusion proteinEnzymesEpigenetic ProcessEventEwings sarcomaFoundationsGene ExpressionGene ProteinsGeneticGlucoseGlycogenGlycogen (Starch) SynthaseGoalsHistonesHomeostasisIn VitroIncidenceKnock-outLearning SkillMalignant Childhood NeoplasmMalignant NeoplasmsMetabolicMetabolismMetastatic Ewing&aposs SarcomaModelingModificationNude MiceOncogenesOperative Surgical ProceduresPathogenicityPathologicPathologyPatientsPatternPeriodic acid Schiff stain methodPhosphorylationPositioning AttributePrimary NeoplasmProliferatingProtein KinaseProteinsRecurrenceResearchResearch PersonnelResolutionRoleSamplingStructureSurvival RateTechniquesTherapeuticTimeTrainingTranslatingWorkXenograft Modelbasebonecancer cellcareerchemotherapydesignepigenetic regulationglucose metabolismglycogen metabolismhistone modificationin vitro Assayin vivoinhibitor/antagonistinnovationinorganic phosphateinsightirradiationlipid metabolismmacrophagemetabolomicsmultidisciplinarynovelnovel therapeutic interventionnovel therapeuticspersonalized medicinepolyglucosanpost-doctoral trainingpre-doctoralprotein functionrare cancersoft tissuestable isotopestandard of caretherapeutic targettreatment strategytumortumor growthtumor metabolismtumorigenesis
项目摘要
Project Summary
Ewing's sarcoma (ES) is the second most common pediatric bone malignancy affecting ~10,000 children,
adolescents, and young adults worldwide each year. Approximately half of all patients with Ewing's sarcoma
will develop either recurrent or metastatic disease with less than 20% of such patients surviving long-term. The
standard of care for ES patients includes multi-agent chemotherapy to treat documented or potential metastatic
disease, coupled with surgery and/or irradiation to treat the primary tumor. Although some incremental
advances have been made in the last three decades through intensification of conventional chemotherapy
agents, more significant improvements will likely depend on the identification of novel treatment strategies.
Two hallmark clinical features of ES are: 1) the accumulation of intracellular glycogen deposits that are
Periodic acid-Schiff positive (PAS+) during pathological analysis, and 2) the EWS-FLI1 fusion oncogene.
Contribution of EWS-FLI1 to tumorigenesis and epigenetics is well defined, but little is known about the biology
and pathology of ES glycogen accumulation nor has ES glycogen metabolism been explored as an anti-ES
target.
The aims presented in this proposal are designed to interrogate the role of glycogen metabolism in
promoting tumorigenesis in ES and extend my career in cancer metabolism. My preliminary data demonstrate
glycogen in ES models has aberrant architecture with long chains, increased branching pattern, and high
phosphate content. Thus, this glycogen is more similar to pathogenic polyglucosan bodies (i.e. ES-PGBs) and
disrupts normal cellular processes. Excitingly, I have demonstrated that targeting ES-PGBs using a glycogen
synthase inhibitor reduces in vivo tumor growth. I will expand on these findings in Aim 1 by demonstrating ES-
PGBs alter cellular energy homeostasis utilizing high-throughput metabolomics profiling and innovative
biochemical assays in vitro and in vivo. These results will advance our understanding of glycogen metabolism
in ES and have broad implications for designing new therapeutic options for ES patients. In Aim 2, I plan to
extend my predoctoral training in cellular metabolism of a rare cancer to my postdoctoral training in the
emerging field of cancer metabolism's role in epigenetic regulation. I have received excellent training in the
field of glycogen metabolism in cancer and I believe this foundation will help answer key outstanding questions
in the utilization of key metabolites to control gene expression and protein function. Cumulatively, this proposal
provides time in both my predoctoral and postdoctoral training to learn skills necessary to achieve my goal of
an independent investigator in cancer metabolism.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Lyndsay E A Young其他文献
Lyndsay E A Young的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Lyndsay E A Young', 18)}}的其他基金
Aberrant Glycogen Modulates Metabolism in Ewing’s Sarcoma
异常糖原调节尤文氏肉瘤的代谢
- 批准号:
10473896 - 财政年份:2021
- 资助金额:
$ 3.97万 - 项目类别:
相似海外基金
Pharmacological targeting of AMP-activated protein kinase for immune cell regulation in Type 1 Diabetes
AMP 激活蛋白激酶对 1 型糖尿病免疫细胞调节的药理学靶向
- 批准号:
2867610 - 财政年份:2023
- 资助金额:
$ 3.97万 - 项目类别:
Studentship
Establishing AMP-activated protein kinase as a regulator of adipose stem cell plasticity and function in health and disease
建立 AMP 激活蛋白激酶作为脂肪干细胞可塑性和健康和疾病功能的调节剂
- 批准号:
BB/W009633/1 - 财政年份:2022
- 资助金额:
$ 3.97万 - 项目类别:
Fellowship
Determining the role of AMP-activated protein kinase in the integration of skeletal muscle metabolism and circadian biology
确定 AMP 激活蛋白激酶在骨骼肌代谢和昼夜节律生物学整合中的作用
- 批准号:
532989-2019 - 财政年份:2021
- 资助金额:
$ 3.97万 - 项目类别:
Postdoctoral Fellowships
Metabolic control of integrin membrane traffic by AMP-activated protein kinase controls cell migration.
AMP 激活的蛋白激酶对整合素膜运输的代谢控制控制着细胞迁移。
- 批准号:
459043 - 财政年份:2021
- 资助金额:
$ 3.97万 - 项目类别:
Studentship Programs
Determining the role of AMP-activated protein kinase in the integration of skeletal muscle metabolism and circadian biology
确定 AMP 激活蛋白激酶在骨骼肌代谢和昼夜节律生物学整合中的作用
- 批准号:
532989-2019 - 财政年份:2020
- 资助金额:
$ 3.97万 - 项目类别:
Postdoctoral Fellowships
The Role of AMP-activated Protein Kinase in GVHD-causing T Cells
AMP 激活的蛋白激酶在引起 GVHD 的 T 细胞中的作用
- 批准号:
10561642 - 财政年份:2019
- 资助金额:
$ 3.97万 - 项目类别:
Determining the role of AMP-activated protein kinase in the integration of skeletal muscle metabolism and circadian biology
确定 AMP 激活蛋白激酶在骨骼肌代谢和昼夜节律生物学整合中的作用
- 批准号:
532989-2019 - 财政年份:2019
- 资助金额:
$ 3.97万 - 项目类别:
Postdoctoral Fellowships
Treating Diabetic Inflammation using AMP-Activated Protein Kinase Activators
使用 AMP 激活的蛋白激酶激活剂治疗糖尿病炎症
- 批准号:
2243045 - 财政年份:2019
- 资助金额:
$ 3.97万 - 项目类别:
Studentship
The Role of AMP-activated Protein Kinase in GVHD-causing T Cells
AMP 激活的蛋白激酶在引起 GVHD 的 T 细胞中的作用
- 批准号:
10359032 - 财政年份:2019
- 资助金额:
$ 3.97万 - 项目类别:
Investigating the therapeutic potential of AMP-activated protein kinase in myotonic dystrophy type 1
研究 AMP 激活蛋白激酶在 1 型强直性肌营养不良中的治疗潜力
- 批准号:
428988 - 财政年份:2019
- 资助金额:
$ 3.97万 - 项目类别:
Studentship Programs